The industry standard Phase 2 to Phase 3 progression rate for metabolic disorders is 45%, and the Phase 3 success rate is 63.6%
Are compounded GLP-1s safe after the February 2026 FDA warning letters
3 , e2022942 (2020)
Similarly, in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model, GLP-1 analogues were reported to protect the brain from MPTP-induced pathological effects, such as movement disorders, increased levels of -synuclein, chronic inflammation in the brain, loss of dopaminergic neurons, oxidative stress, and expression of growth factors (65)
Research is limited yet some studies have found that oral collagen supplements produce substantive improvements to skin elasticity as well as joint mobility